IMUX is trading 5.3% down today at $14.55 on likely profit-taking following yesterday’s outperformance versus a weak U.S. market.
- No new earnings, clinical trial data, FDA decisions, or major analyst calls have been reported today.
- The move follows a period of relative strength, with the most recent company news dating back to the May 13, 2026, Q1 results and financing update.
- Today's price action appears to be sentiment-driven rather than a response to fresh, company-specific developments.